Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07637474

Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients

Conditions: Nsclc

Sex: All

Ages: 18 Years – N/A

Enrollment: 150

Sponsor: Regina Elena Cancer Institute

Location: IRCCS National Cancer institute Rome Rome

Summary

Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years * Histological diagnosis of advanced stage NSCLC * Histotype adenocarcinoma and squamous carcinoma * ECOG PS \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07637474). StuddyBuddy aggregates publicly available trial information.